

**Webinar on IMI2 - Call 16: AMR Accelerator programme - Pillar C: Portfolio Building Networks to advance the R&D pipeline of new and innovative agents to address AMR**



First Name	Last Name	Email	Country	Organization	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Amélie	Abrantes	amelie.abrantes@u-bordeaux.fr	France	Université de Bordeaux	
ITZIAR	ACHA	iacha@bioef.org	Spain	Fundación Vasca de Innovación e Investigación Sanitarias - BIOEF	
Jose	Ainsa	ainsa@unizar.es	Spain	UZ	Expertise in drug discovery and resistance, with mycobacteria and other pathogens
Edita	Bagdonaite	edita.bagdonaite@mita.lt	Lithuania	Agency for Science, Innovation and Technology	
Patrick	BOISSEAU	patrick.boisseau@cea.fr	France	CEA	nanocarrier with therapies against microbial infections
Krista	Braet	kbraet@its.jnj.com	Belgium	Janssen Pharmaceutica	
Célia	Cabral	celia.cabral@fmed.uc.pt	Portugal	Faculdade de Medicina, Universidade de Coimbra	
Laura	Castaneda	laura@plasmabiotech.com	Spain	Plasmia Biotech SL	Library of molecules, expertise in medical chemistry and Drug Discovery processes.
Corentin	Chaboud	corentin.chaboud@bioaster.org	France	BIOASTER	preclinical models, in-vivo imaging, PK/PD evaluation, metabolic screening of antimicrobial mechanism of actions (metSAMoA)
Aurelien	Chollet	aurelien.chollet@antabio.com	France	Antabio SAS	Antabio is a SME dedicated to the R&D of innovative programs to tackle the antimicrobial resistance. We have two lead programs
matthias	cleenewerck	mcleenew@its.jnj.com	Belgium	JNJ	PM
Rene	Coppens	rene.coppens@tbvi.eu	Netherlands	TuBerculosis Vaccine Initiative	Scientific coordination / Project management
Kim	Cryns	kcryns@its.jnj.com	Belgium	Janssen	
Aniek	Doensen	aniek.doensen@catalyze.nl	Netherlands	Catalyze	
Damien	Dupin	ddupin@cidetec.es	Spain	Fundación CIDETEC	Nanoparticles/anocarrier expert to deliver antibiotics. owner of patented technology on nanocarrier that improve antibiotics.
María Emilia	Fernández-Prieto Pérez	mefernandez-prieto@pharmamar.com	Spain	PharmaMar	30 years of experience in marine biotech; our core business is oncology; we have the world's largest collection of marine organism
Astrid	Flandorfer	astrid.flandorfer@ffg.at	Austria	FFG	
Paula	Garcia	pgarcian@idibell.cat	Spain	Bellvitge Biomedical Research Institut	
Mireia	Gimenez	mgimenez@leitat.org	Spain	LEITAT	Extensive preclinical models; in depth mechanism of action investigation; biodistribution; organoid technology; Biosensors; NPs.
Jonathan	Gomez-Raja	jonathan.gomez@fundesalud.es	Spain	FundeSalud, Government of Extremadura	Hospitals (14), patients and expertise in infectious diseases and EU projects
Concepción	González-Bello	concepcion.gonzalez.bello@usc.es	Spain	Universidade de Santiago de Compostela, CIQUS	novel targets, synthesis, structure-based design, irreversible inhibitors, MD simulations, crystallization enzyme/inhibitor
Jakob	Haardt	j.haardt@eurice.eu	Germany	EURICE GmbH	Expertise in collaborative project management and exploitation management (management partner in running IMI projects)
John	Hays	J.HAYS@ERASMUSMC.NL	Netherlands	Erasmus MC	Animal Models of infection including nanoparticle-antibiotic combination testing (www.pneumonp.eu)
Skriwanek	Jan	jan.skriwanek@dlr.de	Germany	National Contact Point Health Germany	
Wim-Jan	Koot	wim-jan.koot@lygature.org	Netherlands	Lygature	Project/Partnership Management, Data Management, Regulatory Expertise, Patient Engagement (in short: partnership infrastructure)
Julio	Mancera	julio.mancera@cloverbiosoft.com	Spain	Clover Biosoft	Wide experience in MS MALD-TOF and bioinformatics
Jesus	Martinez	jmfuente@unizar.es	Spain	CSIC	Synthesis, characterisation and bio functional inaction of nanocapsules

Fabrice	NAVARRO	fabrice.navarro@cea.fr	France	CEA LETI	expertise in nanomedicine, for the targeted delivery of antimicrobial agents to the desired sites
Marie	Olliver	marie.olliver@ilk.uu.se	Sweden	Uppsala Universitet	
Ameeta	Parekh	ameeta.parekh@fda.hhs.gov	United States	FDA CDER	
Claudia	Pfander	pfander@arttic.eu	France	ARTTIC	Project Management Services with focus on IMI2, Dissemination
Elodie	Pfender	elodie.pfender@chu-limoges.fr	France	CHU Limoges	Expertise in clinical research in the ICU field and in Phase 1 ; already partner of several COMBACTE projects (ND4BB program)
Isabelle	PHILIPPE	isabelle.philippe@cea.fr	France	CEA Joliot Institute	
Nadège	PREL	nadege@affilogic.com	France	AFFILOGIC	
Santiago	Ramon Garcia	san tiramon@unizar.es	Spain	Research & Development Agency of Aragon (ARAID) Foundation	Drug profiling, combination studies, in vitro and in vivo models, PKPD modeling, MoA studies, new BDQ synergistic partners
Sònia	Sagristà	ssagrista@idibell.cat	Spain	IDIBELL	
Ruth	Schmid	ruth.b.schmid@sintef.no	Norway	SINTEF AS	polymeric and lipid nanoparticles, physico-chemical characterization and in vitro toxicity and efficacy cell-based assays -2D/3D
Younes	Smani	ysmani-ibis@us.es	Spain	Institute of Biomedicine of Seville	—
Graham	Somers	graham.i.somers@gsk.com	United Kingdom	GSK	
Rob	Stavenger	robert.a.stavenger@gsk.com	United States	GlaxoSmithKline	IMI project leadership, antibacterial drug discovery, medicinal chemistry
Michela	Tacca	m.tacca@uke.de	Germany	University Medical Centre Hamburg-Eppendorf	
Andrea	Tamellini	andrea.tamellini@bioaster.org	France	BIOASTER	Animal models of infection (nosocomial infections, multiple pathogens, organ targeting), Immunotox HIS mice, in vivo imaging
Remko	van Leeuwen	remko.vanleeuwen@madam-therapeutics.com	Netherlands	Madam Therapeutics	Effective new antimicrobials with a novel mechanism of action
Sara	Vicente	svicenteo@ibecbarcelona.eu	Spain	Institute for Bioengineering of Catalonia (IBEC)	Molecular mechanisms of bacterial infections/biofilms, identify antibacterial molecules/targets; nanomedic. applied to microbiol
Ana	Vila	ana.vila@inl.int	Portugal	INL - International Iberian Nanotechnology Laboratory	
Andrea	Zaliani	andrea.zaliani@ime.fraunhofer.de	Germany	Fraunhofer IME	